This document provides a competitor analysis for lactoferrin products in the Egyptian market. It analyzes key competitors including Pravotin, Dulefer, and Rovitan. Pravotin has the largest market share and is the main competitor. The document also examines the lactoferrin market size, current treatment approaches, customer types, and strengths and weaknesses of different products. Key information on sales, prescription trends, and relationships with customers are outlined to inform marketing and sales strategies.

1. Competitors analysis

2. Vitosel
• MS =
• Units = 30138
• PPG = 58.5%
• Value = 1313898 l.e

3. External Analysis, Market Definition (Dimensions)
• Lactoferrin market,
• ANAE COMP PR/CH/PRP O99-0
• ANAEMIA UNSPECIFIED D64-9
• DIS DIG SYST PR/CH/PRP O99-6
• AC UPP RESP INFECT UNSP J06-9
• PNEUMONIA UNSPECIFIED J18-9
• COVID-19 VIRUS NOT IDENT U07-2
Target Market: Patients &
Indications
• Total Market MAT 06.2020 : Value = 149,619,468 EGP ,Units = 1,591,918
• Market leader : Pravotin Value= 105,524,936 Units= 1,000,162
Size of the market
• Lactoferrin as antimicrobial & Prevention from IDA
Current treatment
classes/approaches
• Chest ,G.P &IM,ped
• UCP ,IbnSina ,ECTD ,Pharam ,Watnia
• Street Pharmacy ,Chain
Current customers
• Pravotin is the Direct competitor
Competition
• Key events that change fundamentally Market dynamics (Pandemic diseases , Forte,
antimicrobial ,…?
Market events/milestones

4. Competitor Analysis ( IMS DATA)
Product PRAVOTIN DULEFER Rovitan
Company Hygint Dulexlab golbe
Active ingredient Lactoferrin 100 mg Lactoferrin 100mg lactoferrin
Form
Sachets
7
14
30
sachets 14 Sachets 14
Price 55 le
85le
165 le
75le 98 le
Launch 2017 2020
Dose frequent
Unit/Rx”IMS”

5. Competitor Analysis
Product Strengths Weaknesses
Pravotin
1.Well Established Products
2.High KOL relationship
3.Good availability
4.Very strong relations with targeted
segment
5.Sales offers
6.strategic product in Hygint
7.Has highly engaged facebook page
• Low coverage in Cairo,Giza
&U.E
MKT leader pravotin
hygient
value 105.59
78%
unit 105 M
73%
PPG
28%

6. Competitor Analysis
Product Strengths Weaknesses
DULEFER
1.Well Established Products
2.Good availability
3.Very strong relations with targeted
segment
4.Sales offers
5. covid 19 treatment at ministry of health
• Low coverage in Cairo,Giza
&U.E
• Bad image for dulexlab
MKT leader
value 9,752,000 EGP
unit 212,000
PPG 27%

7. value
• MS % =

8. Competitor Analysis ( IMS DATA)
Product BRONCHO-VAXOM IMMUGUARD IMMULANT
KALOBIN SANSOIMUNE
Company MINAPHARM Dulex lab MEPACO MARCYRL(HSO) AUG
Active ingredient
STAPH, STREPT,
HAEMOPHILUS
B.Colostrum ECHINACEA PELARGONIUM ECHINACEA,Zn,VitC
Form 10 SACHETS 10 CAPS 7 SACHETS 14 SACHETS
120 ml SYRUP 20 ml DROPS 200 ml SYRUP
Price 55 60 55 95 23.5 23 26
Launch 7/2008 4/1989 11/2013 1/2015 4/2004 1/2011 9/2019
Dose frequent Once 82% Once 40% Three times 61% Three times 73% Twice
Unit/Rx”IMS” 10 8 5 5 51

9. Product BRONCHO-VAXOM IMMULANT
KALOBIN SANSOIMUNE
Strength Points
• Good reputation for
respiratory infection
• 2 form sachet and capsule
• Low Price
• Strong Rx in Delta
• Low Price
• Good reputation especially
under 4 years age
• Strong Rx in UE
• Low Price
• Vit.C and Zinc = Immunity
ingredient trend
• 200 ml = long duration
Weak Points
• reputation for respiratory
disease only
• Weak Geographical Rx in
other area
• reputation for young age
only
• Weak prescription allover
Egypt

10. Customer/Consumer Type Product Relation People Relation
Comments
Pediatrician ++++ +++
• Focus on efficacy
• Preparation new studies
Pharmacists +++ ++
• Make special offers
Parents ++ +++++
• Social media
• Pharmacy flayer

12. Sales
1st Qtr 2nd Qtr 3rd Qtr 4th Qtr